Skip to main content


for people ages 1–21 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:



This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.

Official Title

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia


ALL (Acute Lymphoblastic Leukemia) B-cell acute lymphoblastic leukemia (ALL) pediatric multi-agent chemotherapy JAK inhibitor Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid Dexamethasone Prednisone Pegaspargase Cyclophosphamide Doxorubicin Methotrexate Cytarabine Vincristine Asparaginase 6-Mercaptopurine Thioguanine Levoleucovorin


You can join if…

Open to people ages 1–21

  • Eligible Ages in Australia and Canada; 2 years to 21 years
  • De novo high-risk (HR) Ph-like B-ALL for which any of following criteria are present at diagnosis:
  • Age ≥ 10 years
  • White blood cell (WBC) ≥ 50 × 103/μL

  • CNS3 leukemia
  • Systemic steroid pretreatment without presteroid WBC documentation
  • One of the following Ph-like ALL genetic lesions must be present in the diagnostic bone marrow or peripheral blood sample:
  • CRLF2 rearrangement with JAK1 or JAK2 mutation (JAK+)
  • CRLF2 rearrangement without JAK mutation
  • Other JAK pathway alterations (eg, JAK2 fusions, erythropoietin receptor (EPO-R)fusions, SH2B3 deletions, interleukin-7 receptor-alpha (IL7RA) mutations) with or without CRLF2 rearrangement
  • Completed a 4-drug Induction therapy regimen (modified aBFM regimen or equivalent) in Study AALL1131 or as the institutional standard of care for HR B-ALL and have had end-Induction minimal residual disease (MRD) assessed
  • Male and female subjects of reproductive non childbearing potential or willing to take appropriate precautions to avoid pregnancy or fathering a child for the duration of study participation

You CAN'T join if...

  • Receipt of any other cytotoxic chemotherapy before Induction therapy, with exception of hydroxyurea or steroid pretreatment
  • Trisomy 21 (Down syndrome)
  • BCR-ABL1-rearranged (Ph+) ALL
  • Calculated creatinine clearance or radioisotope glomerular filtration rate < 70 mL/min/1.73 m2

  • Alanine aminotransferase ≥ 5 × upper limit of normal (ULN) for age
  • Direct bilirubin ≥ 1.5 × ULN (may be assumed if total bilirubin is below ULN)
  • History or evidence of cirrhosis
  • Platelet count < 75 × 103/μL

  • Absolute neutrophil count (ANC) < 750/μL
  • Positive screen for hepatitis B or C
  • Known human immunodeficiency virus infection


  • UCSF Pediatric Hematolgy/Onclgy accepting new patients
    San Francisco, California, 94143, United States
  • Kaiser Permanente Medical Center - Northern California not yet accepting patients
    Oakland, California, 94611, United States
  • Valley Children's Hospital accepting new patients
    Madera, California, 93636, United States
  • Lucille Packard Child Hospital END accepting new patients
    Palo Alto, California, 94304, United States
  • Children's Hospital Los Angeles accepting new patients
    Los Angeles, California, 90027, United States
  • Southern California Permanente Medical Group accepting new patients
    Los Angeles, California, 90027, United States
  • Kaiser Permanente Downey (Satellite Site) accepting new patients
    Downey, California, 90242, United States
  • Miller Children's at Long Beach Medical Center accepting new patients
    Long Beach, California, 90806, United States
  • Kaiser Permanente Fontana (Satellite Site) accepting new patients
    Fontana, California, 92335, United States
  • Kaiser Permanente Anaheim (Satellite Site) accepting new patients
    Anaheim, California, 92806, United States
  • Children's Hospital of Orange County accepting new patients
    Orange, California, 92868, United States
  • Loma Linda University Cancer Center accepting new patients
    Loma Linda, California, 92350, United States
  • Children's Specialty Center of Nevada accepting new patients
    Las Vegas, Nevada, 89109, United States


accepting new patients
Start Date
Completion Date
Incyte Corporation
Phase 2
Lead Scientist
Mignon Loh
Study Type
Last Updated
December 7, 2017
I’m interested in this study!